Study wrapper · #1052
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Rantanen R, Olson C, Raval C Journal of clinical psychopharmacology. 2026.
DOI: 10.1097/jcp.0000000000002241PubMed: 42495981
Editor's note
A single-patient case report describing weight loss on tirzepatide accompanied by a bipolar disorder exacerbation in the context of clozapine therapy. The possible interaction is noteworthy for clinicians, but a case report cannot separate the medication's role from the underlying illness course. No abstract was available to evaluate further detail.
Plain-language abstract
This single case report describes tirzepatide-associated weight loss alongside a worsening of bipolar disorder in a patient also taking clozapine. As a single case, it cannot establish a causal link.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026